Article Text

Download PDFPDF
Intravenous levetiracetam: a new treatment alternative for refractory status epilepticus
  1. G Möddel1,
  2. S Bunten2,
  3. C Dobis3,
  4. S Kovac1,
  5. M Dogan1,
  6. M Fischera1,
  7. R Dziewas1,
  8. W-R Schäbitz1,
  9. S Evers1,
  10. S Happe2
  1. 1
    Department of Neurology, University of Münster, Münster, Germany
  2. 2
    Department of Clinical Neurophysiology, Klinikum Bremen-Ost/University of Göttingen, Bremen, Germany
  3. 3
    Department of Neurology, St Marien-Hospital, Lünen, Germany
  1. Dr G Möddel, Department of Neurology, University of Münster, Albert-Schweitzer-Strasse 33, 48129 Münster, Germany; moddel{at}


The purpose of this study was to investigate the safety and efficacy of intravenous levetiracetam (LEV-iv) in refractory status epilepticus (SE). A retrospective chart review was performed on patients who received LEV-iv for treatment of SE (n = 36) and had failed at least one other antiepileptic drug. LEV-iv (median 3000 mg/day; range 1000–9000) was administered as a bolus loading (500–2000 mg per 30–60 min, n = 30) or as a continuous pump infusion (n = 6). SE was terminated in 69% (“responders”); 31% (“non-responders”) remained in SE. Factors associated with failure were: dose escalation over 3000 mg/day, lack of bolus loading, treatment latency over 48 h, age over 80 years, non-convulsive SE with coma (“subtle SE”), periodic lateralised epileptiform discharges (PLEDs) on EEG, acute cerebral lesion and intubation narcosis. SE was terminated in all eight patients without brain lesion (p = 0.033), and in all seven patients with complex partial SE (p = 0.051). Outcome was favourable (ambulatory patients) in 48% (responders) compared with 0% (non-responders), and “adverse” (death or continuing coma/stupor) in 24% (responders) compared with 100% (non-responders). Mortality was 17% (responders 4%, non-responders 45%). No patient had cardiocirculatory side effects or worsening of SE. Two patients experienced nausea and vomiting during LEV-iv loading, leading to aspiration pneumonia in one. This study suggests that LEV-iv may be a safe and efficacious treatment of SE. Prospective and controlled trials are imperative to confirm these preliminary findings.

Statistics from


  • Competing interests: None.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.